#USA #Chicago #oncology #Phanes Therapeutics #Spevatamig

Phanes Therapeutics to Present Updated Phase 2 Results of Spevatamig in Combination with Chemotherapy

Phanes Therapeutics, Inc., a biotech firm dedicated to ground-breaking drug development in the oncology sector, is poised to present its updated Phase 2 clinical trial findings of Spevatamig (PT886) at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. This event is scheduled to take place from May 29 to June 2, 2026, in Chicago. The study focuses on the use of Spevatamig in conjunction with chemotherapy for frontline treatment among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), a particularly aggressive form of cancer.

Presentation Details

The presentation is planned for May 30, 2026, from 9:00 AM to 12:00 PM CDT, and is set within the Gastrointestinal Cancer session, which covers various topics related to cancers of the stomach, pancreas, and bile ducts. The presentation will carry the abstract number 4192 and will be displayed as poster number 175. The first author of the presentation is Dr. Anwaar Saeed from the University of Pittsburgh Medical Center.

Spevatamig, designed as a bispecific antibody, specifically targets claudin 18.2 and CD47, making it a leading candidate in the treatment landscape for pancreatic cancer.

About Spevatamig

Spevatamig stands out as a first-in-class therapy that harnesses an innovative mechanism through its native IgG-like bispecific antibody structure. This unique formulation is engineered to target specific cancer markers in pancreatic cancer patients. In 2022, the FDA designated Spevatamig as an orphan drug, acknowledging its potential in treating pancreatic cancer. This path was further accelerated with the Fast Track designation the drug received in 2024 for patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma.

Phanes Therapeutics has been at the forefront of pushing further clinical études, establishing a collaborative relationship with Merck for studies involving Spevatamig and pembrolizumab, a drug that enhances the immune response against tumors.

As of April 2026, 180 patients globally have been dosed with Spevatamig across various treatment scenarios, including both monotherapy and combination therapy, reflecting the ongoing commitment of Phanes to refine the efficacy of its breakthrough therapies.

Phanes Therapeutics Overview

Phanes Therapeutics aims to carve a niche in oncology through its revolutionary approaches to drug discovery and development. The firm is currently involved in multiple ongoing clinical trials for its key candidates, including Spevatamig and Peluntamig, alongside Mavrostobart. Spevatamig and Peluntamig are notable for their class-leading bispecific antibody configurations, both of which have successfully secured orphan drug and Fast Track statuses from the FDA.

By leveraging proprietary technology platforms like PACbody®, SPECpair®, and ATACCbody®, Phanes Therapeutics is committed to addressing critical unmet medical needs within cancer treatment. The company continues to innovate and push boundaries, demonstrating a strong pipeline of promising therapies aimed at new frontiers in oncology.

For comprehensive details about Phanes Therapeutics, including their latest trials and innovations, interested parties are encouraged to visit their official site: www.phanesthera.com. For any inquiries relating to business development or media interactions, contact information for relevant departments is readily available.